Support in USA : 1-978- 707-9553 / Support in India : +91- 9987711567

  • Apple Pharmaceuticals



Availability: In stock

Special Price $ 125

BRAND : Geftinat
STRENGTH : 250mg
INGREDIENT : Anticancer-Cancer-Treatment-Natco-Geftinib-250mg-Geftinat
COUNT : 30 Tablets

Description of Geftinat

Description: Geftinat (Gefitinib) is a signal transduction inhibitor. Gefitinib is the generic for the trade name of Tablet Geftinat Geftinat is classified as targeted therapy which means to target the epidermal growth factor receptor tyrosine kinase inhibitor Geftinat is the prescription medicine; it is given to the patients under the guidance of medical oncologist Product information: Brand name: Geftinat Active ingredient: Gefitinib Strength: 250MG Mfg: Natco pharma Package: 30 tablets in a container Category: Anti-neoplastic or Tyrosine kinase Inhibitor

Pharmacology of Geftinat

Geftinat mechanism of action Geftinat tablets are anti-cancer medicine which involved in by prohibiting the epidermal growth factor receptor tyrosine kinase by binding to adenosine triphosphate binding region of the enzyme. The activity of EGFR tyrosine kinase is signal transduction to malignant cells Thus the activity of EGFR is inhibited and growth of cancer cells also prohibits Pharmacokinetic: Absorption: Geftinat is slowly absorbed in the body after oral administration The mean bioavailability of the drug is 60% The peak plasma concentration of the drug Gefitinib is occur within 3-7 hours Distribution: Human plasma protein bound with Geftinat around 90% The volume of distribution is 1400L Metabolism: The metabolism of the drug Gefitinib occurs majorly in liver. With the help of cytochrome isoenzymes CYP3A4 metabolism occurs Elimination: The routes of elimination of metabolites are through feces and urine Feces 86% Urine 4% The terminal half life time of Geftinat tablet is 48 hours

Indication of Geftinat

Geftinat is ideally used for the treatment of; Advanced or metastatic non-small cell lung cancer Geftinat is used only after failure of both platinum based and taxane based chemotherapies

Dose & Dosage's of Geftinat

Geftinat tablets are mainly used for metastatic non-small cell lung cancer; The usual dose of Geftinat tablet is 250mg should be taken orally with or without food as a single dose If patient unable to administered, tablets should be dissolve in 4 to 8 ounces of plain non-carbonated water and drink immediately Dosage modification: The dosage of the tablet Geftinat should be altered in case of; Acute onset or worsening pulmonary symptoms Elevation of Alt & AST Diarrhea, ocular disorders, skin reactions Permanently discontinue the Tablet Geftinat in case of; Confirmed interstitial lung disease Persistent ulcerative keratitis Gastrointestinal perforation Severe hepatic impairment Concomitant with strong CYP3A4 inducers; Increase the dose of Geftinat to 500mg orally as a single dose if no adverse reaction produces Restart to 250mg orally as a single dose after discontinuation of CYP3A4 strong inducers In pediatric: The safety and efficacy of tablet Geftinat has not been established Missed dose: If patient fail to take Geftinat tablet, they may get advice from medical practitioner (oncologist) for administration of the missed dose within the time Otherwise the missed dose should be skipped and follow the next dosing schedule Do not double the dose

Side Effects of Geftinat

>10% of patients get; Skin reaction, diarrhea, loss of appetite, vomiting, increased ALT 1-10% of patients occurred; Elevation of AST, stomatitis, conjunctivitis, blepharitis, dry eye, elevation of ALT, nail disorders, diarrhea, increased bilirubin levels, loss of appetite, interstitial lung disease <1% of patients have chance to get; Interstitial lung disease, hyperbillirubemia, stomatitis, corneal erosion, aberrant eyelash growth, nail disorders, gastrointestinal perforation, ocular keratitis, Erythema multiforme and dermatitis Bullous, fatal hepatoxicity Post marketing reports: Renal and urinary disorders: cystitis, hemorrhagic cystitis Skin and subcutaneous tissue disorders: cutaneous vasculitis

Contraindication of Geftinat

Geftinat contraindicated; If patient taking Geftinat tablet, they may have chance to get anaphylactic reactions

Drug Interaction of Geftinat

Asunaprevir, Bosentan, Ceritinib, cobicistat, conivaptan, CYP2D6 inhibitors (moderate and strong), CYP3A4 inducers (moderate and strong), CYP3A4 inhibitors (moderate and strong), Dabrafenib, darunavir, dasatinib, deferasirox, Enzalutamide, fosaprepitant These are some drugs which will interfere with serum concentration of cytochrome isoenzymes H2 receptor antagonist and proton pump inhibitors: co administration with Geftinat, decrease the serum concentration of Gefitinib Vitamin K antagonist: Geftinat increase the anti-coagulant effect of vitamin K antagonist like warfarin Abiraterone acetate: increase the serum concentration of CYP2D6 substrates Ajmaline: increase the serum concentration of CYP2D6 substrates Antacids: decrease the serum concentration of Gefitinib Aprepitant: increase serum concentration of CYP3A4 substrates

Precaution of Geftinat

While patient taking Geftinat tablet, Caution should be taken in the conditions like; Dermatological toxicity Gastrointestinal effects Hepatotoxicity Ocular toxicity Pulmonary toxicity Hepatic toxicity

Usage & Safety profile of Geftinat Pregnancy & Lactation

Pregnancy category: C Geftinat generally not recommended in pregnancy condition, because it may cause fetal harm Breast feeding is also not recommended, the metabolites of Geftinat tablets are excreted in human milk. It transfer through milk to babies and cause harm

Storage of Geftinat

The storage condition of Geftinat tablet; Store in cool and dry place Protect from direct sunlight Keep out of reach from children and animal